Introduction

77
Tumor angiogenesis is a hallmark of cancer and requires the coordinated actions of (2); however overlapping and compensatory alternative angiogenic pathways provide 83 escape mechanisms that likely limit the full potential of VEGF monotherapies (3).
84
The Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2 (Ang-1 and Ang-2), Ang-2-VEGF-A CrossMab is being developed for the treatment of multiple cancer 117 indications aiming to substantially improve clinical outcomes.
118
In this study, we evaluated the therapeutic potential of Ang-2-VEGF-A CrossMab.
Material and Methods
126
Therapeutic antibodies and treatment. A2V CrossMab (anti-human VEGF-A and 127 anti-human/murine Ang-2; Fig. S1A ) was generated as previously described (23). 
Results
149
Ang-2-VEGF-A CrossMab retards tumor growth in orthotopic and 150 subcutaneous cancer models at later stages of tumor development.
151
Based on a method for the generic production of bivalent bispecific human IgG1 152 antibodies (23), we have generated a human IgG1 antibody neutralizing VEGF-A
153
and Ang-2 function simultaneously ( Fig. S1A and B) . Bevacizumab was selected as 154 the parental antibody and the light chain was left unaltered, whereas a CH1-Cκ (data not shown), and exhibits identical cross-reactivity and affinity as the respective 162 parental antibodies (Fig. S2 ).
163
First, we investigated the functional consequences of Ang-2-VEGF-A inhibition in 164 orthotopic slowly growing KPL-4 breast tumors expressing human Ang-2 (Fig. S3A ).
165
The tumors were treated when they reached a mean tumor size of 70 mm showed a mean tumor burden (mtb) of 431.5 ± 67.5 mm 3 at the end of the anti-Ang-2 (Fig. 1A, were observed (data not shown). Moreover, an improved median overall survival 197 was observed after A2V CrossMab treatment (Fig. S3E) .
198
The results demonstrate that administration of A2V CrossMab retards tumor growth necrotic and proliferative index were noted ( Fig. 2C and D; Fig. S5A ). Furthermore,
216
in only a small fraction (0.2-0.8%) of the entire tumor area, we observed slight but 217 insignificant increase in tumor hypoxia as detected by CAIX staining (Fig. S5B ).
218
Moreover, we did not observe any major changes in the level of tumor hypoxia in 219 different xenografts at end point analysis ( Fig. S6A and B 
inhibition combined with anti-VEGF-A treatment (using the mouse VEGF-A cross-319 reactive surrogate antibody B20.4-1 (25)) did not aggravate the adverse effect of 320 anti-VEGF-A treatment on healthy vessels (Fig. 6A and B) . On the contrary, (Fig 6A and B, 
383
A non-overlapping toxicity profile will be a determining factor for combining anti- and B20-4.1 (suppl. Table 1 ). pd = patient-derived. Tumor models KPL-4 (70 and 150 mm³) and H460M2 are also described in more detail in the manuscript. 
